# Sleep Number Corp: Form 10-Q for the period ended Sep 28, 2024

- Company: [Sleep Number Corp](/companies/snbrq.md) (CIK 827187)
- Form: 10-Q
- Filed: 2024-11-05
- Accepted by EDGAR: Nov 5, 2024, 16:23 ET
- Period: 2024-09-28
- Accession: 0000827187-24-000091
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/827187/000082718724000091/snbr-20240928.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/827187/000082718724000091/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-09-28.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2024-06-30 to 2024-09-28 | $426.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2023-12-31 to 2024-09-28 | $1.31bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2024-06-30 to 2024-09-28 | $167.1m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2023-12-31 to 2024-09-28 | $528.3m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2024-06-30 to 2024-09-28 | $259.5m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2023-12-31 to 2024-09-28 | $777.2m | us-gaap:GrossProfit |
| Research and development | 3 months, 2024-06-30 to 2024-09-28 | $10.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2023-12-31 to 2024-09-28 | $34.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2024-06-30 to 2024-09-28 | $8.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2023-12-31 to 2024-09-28 | $20.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2024-06-30 to 2024-09-28 | $12.1m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months, 2023-12-31 to 2024-09-28 | $36.6m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months, 2024-06-30 to 2024-09-28 | −$489.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2023-12-31 to 2024-09-28 | −$863.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-06-30 to 2024-09-28 | −$3.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2023-12-31 to 2024-09-28 | −$15.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-06-30 to 2024-09-28 | −$0.14 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2023-12-31 to 2024-09-28 | −$0.69 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-06-30 to 2024-09-28 | −$0.14 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2023-12-31 to 2024-09-28 | −$0.69 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-06-30 to 2024-09-28 | 22,643,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2023-12-31 to 2024-09-28 | 22,588,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2023-12-31 to 2024-09-28 | $50.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2023-12-31 to 2024-09-28 | $17.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2023-12-31 to 2024-09-28 | $728.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2024-09-28 | $1.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-09-28 | $170.3m | us-gaap:AssetsCurrent |
| Total assets | at 2024-09-28 | $864.7m | us-gaap:Assets |
| Current liabilities | at 2024-09-28 | $894.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-09-28 | $1.31bn | us-gaap:Liabilities |
| Current portion of debt | at 2024-09-28 | $516.5m | us-gaap:DebtCurrent |
| Shareholders' equity | at 2024-09-28 | −$448.8m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2024-09-28 | 22,371,000 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 38,262 characters.

### OPERATIONS

Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to provide

a reader of the Company’s condensed consolidated financial statements with a narrative from the perspective of

management on its financial condition, results of operations, liquidity and certain other factors that may affect the

Company’s future results. MD&A is presented in seven sections:

- Forward-Looking Statements and Risk Factors
- Business Overview
- Results of Operations
- Liquidity and Capital Resources
- Non-GAAP Data Reconciliations
- Off-Balance-Sheet Arrangements and Contractual Obligations
- Critical Accounting Policies

### Forward-looking Statements and Risk Factors

### The discussion in this Quarterly Report on Form 10-Q contains certain forward-looking statements that relate to

### future plans, events, financial results or performance. You can identify forward-looking statements by those that

### are not historical in nature, particularly those that use terminology such as “may,” “will,” “should,” “could,”

### “expect,” “anticipate,” “believe,” “estimate,” “plan,” “project,” “predict,” “intend,” “potential,” “continue” or

### the negative of these or similar terms. These statements are subject to certain risks and uncertainties that could

### cause actual results to differ materially from the Company’s historical experience and its present expectations or

### projections. These risks and uncertainties include, among others:

- Changes in economic conditions and consumer sentiment and related impacts on discretionary consumer spending;
- Increases in interest rates, which have increased the cost of servicing the Company’s indebtedness;
- Availability of attractive and cost-effective consumer credit options;
- Ability to achieve savings and efficiencies from cost savings plans related to business restructuring actions and to

avoid unexpected adverse effects;

- Dependence on, and ability to maintain working relationships and favorable contractual terms with key suppliers and

third parties;

- Fluctuations in commodity costs or third-party delivery or logistics costs and other inflationary pressures;
- Risks inherent in global-sourcing activities, including tariffs, foreign regulation, geo-political turmoil, war, pandemics,

labor challenges, foreign currency fluctuations, inflation, and climate or other disasters, and resulting supply

shortages and production and delivery delays and disruptions;

- Operating with minimal levels of inventory, which may leave the Company vulnerable to supply shortages, as well as

carrying excess levels of inventory for various products from time to time, which may leave the Company vulnerable

to inventory obsolescence and write-downs;

- The effectiveness of the Company’s marketing strategy and promotional efforts;
- The execution of the Company’s Total Retail distribution strategy;
- Ability to achieve and maintain high levels of product quality and to improve and expand the product line;
- Ability to protect the Company’s technology, trademarks, and brand and the adequacy of its intellectual property

rights;

- Ability to effectively compete;
- Risks of disruption in the operation of any of the Company’s facilities and operations, including manufacturing,

assembly, distribution, logistics, field services, home delivery, headquarters, product development, retail or customer

service operations;

- Ability to comply with existing and changing government regulations and laws;
- Pending or unforeseen litigation and the potential for associated adverse publicity;
- The adequacy of the Company’s and third-party information systems and costs and disruptions related to upgrading

or maintaining these systems;

### 16 \| 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION

#### Index

- The Company’s ability to identify and withstand cyber threats that could compromise the security of its systems,

result in a data breach or business disruption;

- Risks associated with advancements in or adoption of artificial intelligence technologies;
- The Company’s ability, and the ability of its suppliers and vendors, to attract, retain and motivate qualified and

effective personnel;

- The volatility of the Company’s stock, its removal from various stock indices, and the potential negative effects of

shareholder activism or of changes in coverage by securities analysts;

- Environmental, social and governance risks, including increasing regulation and stakeholder expectations; and
- The Company’s ability to adapt to climate change and readiness for legal or regulatory responses thereto.

### Additional information concerning these, and other risks and uncertainties is contained under the caption “Risk

### Factors” in Part I, Item 1A. in the Company’s Annual Report on Form 10-K and in Part II. Item 1A. in subsequent

### Quarterly Reports on Form 10-Q.

The Company has no obligation to publicly update or revise any of the forward-looking statements contained in this

Quarterly Report on Form 10-Q.

### Business Overview

Sleep Number is a wellness technology company and market leader in the design, manufacturing, marketing and

distribution of innovative sleep solutions. The Company’s purpose is to improve the health and wellbeing of society

through higher quality sleep; to date, it has improved the lives of nearly 16 million people. Sleep Number’s Smart

Sleepers benefit from individualized sleep experiences, night after night, and are experiencing the physical, mental and

emotional benefits of life-changing sleep.

Sleep Number’s life-changing, differentiated smart beds combine physical and digital innovations, integrating

unparalleled physical comfort with a proprietary technology platform. The smart beds offer the Company’s signature

firmness adjustability, enabling each sleeper adjustable comfort. Embedded digital sensors learn the sleep needs of each

individual; “sense and do” technology uses the sensed data to automatically adjust the smart bed to keep the sleeper

comfortable throughout the night. Active temperature balancing technology supports the ideal climate for both sleepers

and solves a prevalent sleep challenge. Additionally, the smart beds are an exceptional value, with personalized sleep

insights delivered daily, new features regularly added to all smart beds through over-the-air updates, at a range of good,

better and best price points. Sleep Number® smart beds provide unique features, benefits and comfort designed for

improved sleep health and wellness for both sleepers.

The Company’s advantaged business model is supported by its consumer innovation strategy: an individualized sleep

wellness platform, an ecosystem of almost 3 million highly engaged Smart Sleepers, a vertically integrated operating

model, and a culture of individuality, with an ambitious vision to become one of the world’s most beloved brands. Sleep

Number’s exclusive distribution supports lifelong customer relationships – through digital and in-store touchpoints – to

provide an exceptional brand experience. The Company’s more than 29 billion hours of longitudinal sleep data enables

strategic collaborations with world-leading health and research institutions, including Mayo Clinic and American Cancer

Society. And Sleep Number’s 3,700 purpose-driven team members are dedicated to the Company’s mission of

improving lives by individualizing sleep experiences.

In the fourth quarter of 2023, Sleep Number began transforming its operating model for greater financial resilience

across a range of economic environments. These cost improvement actions are broad-based. The Company’s

transformation progress, combined with rigorous execution of their differentiated strategy, positions it - when market

growth returns - to capitalize on their innovation leadership, accelerate profitable growth, generate strong cash flow, and

deliver increased value for shareholders. The Company generates revenue by marketing and selling its innovative smart

beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch

points including Stores, Online, Phone, and Chat (Total Retail).

### 17 \| 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION

### Results of Operations

#### Quarterly and Year-to-Date Results

Quarterly and year-to-date operating results may fluctuate significantly as a result of a variety of factors, including

increases or decreases in sales, timing, amount and effectiveness of advertising expenditures, changes in sales return

rates or warranty experience, timing of investments in growth initiatives and infrastructure, timing of store openings/

closings and related expenses, changes in net sales resulting from changes in the Company’s store base, timing of new

product introductions and related expenses, timing of promotional offerings, competitive factors, changes in commodity

costs, disruptions in global supplies or third-party service providers, seasonality of retail and bedding industry sales,

consumer sentiment and general economic conditions. The extent to which these external factors will impact the

Company’s business and its consolidated financial results will depend on future developments, which are highly

uncertain and cannot be predicted. Therefore, the historical results of operations may not be indicative of the results that

may be achieved for any future period.

#### Highlights

Financial highlights for the three months ended September 28, 2024 were as follows:

- Net sales for the three months ended September 28, 2024 of $427 million decreased 10% from $473 million for the

same period one year ago due to the ongoing weakness in the mattress industry and consumers continuing to

scrutinize their spending.

- The net sales change resulted from a 9% comparable sales decrease in Total Retail. For additional details, see the

components of total net sales change on page 19.

- Average sales per store (sales for stores open at least one year, Total Retail, including online, phone and chat) on a

trailing twelve-month basis for the period ended September 28, 2024 totaled $2.7 million, compared with $3.0

million for the same period last year.

- Operating income for the three months ended September 28, 2024 was $8 million, compared with $5 million in the

prior-year period. The $3 million increase in operating income was driven by a $15 million reduction in operating

expenses and a 3.4 ppt. increase in the gross profit rate, offset by lower net sales. Operating expenses for the three

months ended September 28, 2024 included $2 million of restructuring costs.

- Adjusted EBITDA for the three months ended September 28, 2024 was $28 million, compared to $25 million in the

prior-year period as ongoing gross margin improvements and cost reduction actions partially offset the year-over-

year net sales decline.

- Gross profit rate of 60.8% was 3.4 ppt. higher than the prior-year period. The increase was primarily due to year-

over-year product cost reductions through value engineering and ongoing supplier negotiations and favorable

product mix. See the gross profit discussion on page 20 for additional details.

- The $15 million year-over-year reduction in the Company’s operating expenses was due to lower sales and

marketing and research and development expenses, partly offset by $2 million of restructuring costs.

- Net loss for the three months ended September 28, 2024 was $3 million, compared with a net loss of $2 million for

the same period one year ago. Net loss per diluted share was $0.14, compared with a net loss per diluted share of

$0.10 for the comparable period one year ago.

- The Company’s adjusted return on invested capital (Adjusted ROIC) was 4.5% on a trailing twelve-month basis for

the period ended September 28, 2024, compared with 14.9% for the comparable period one year ago.

- The Company generated $51 million in cash from operating activities for the nine months ended September 28,

2024, compared with $32 million for the same period one year ago.

- Free cash flow provided $34 million for the nine months ended September 28, 2024, compared with using $16

million for the same period one year ago.

- As of September 28, 2024, the Company had $517 million of borrowings under its revolving credit facility.

### 18 \| 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION

The following table sets forth the Company’s results of operations expressed as dollars and percentages of net sales.

Figures are in millions, except percentages and per share amounts. Amounts may not add due to rounding differences.

|  | Three Months Ended September 28, 2024 |  | September 30, 2023 |  | Nine Months Ended September 28, 2024 |  | September 30, 2023 |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net sales | $426.6 | 100.0% | $472.6 | 100.0% | $1,305.5 | 100.0% | $1,458.0 | 100.0% |
| Cost of sales | 167.1 | 39.2% | 201.5 | 42.6% | 528.3 | 40.5% | 612.3 | 42.0% |
| Gross profit | 259.5 | 60.8% | 271.1 | 57.4% | 777.2 | 59.5% | 845.6 | 58.0% |
| Operating expenses: |  |  |  |  |  |  |  |  |
| Sales and marketing | 205.5 | 48.2% | 221.1 | 46.8% | 596.4 | 45.7% | 649.4 | 44.5% |
| General and administrative | 33.1 | 7.8% | 31.9 | 6.8% | 111.7 | 8.6% | 111.1 | 7.6% |
| Research and development | 10.6 | 2.5% | 12.6 | 2.7% | 34.6 | 2.7% | 42.5 | 2.9% |
| Restructuring costs | 2.0 | 0.5% | — | 0.0% | 14.4 | 1.1% | — | 0.0% |
| Total operating expenses | 251.1 | 58.9% | 265.7 | 56.2% | 757.1 | 58.0% | 803.1 | 55.1% |
| Operating income | 8.4 | 2.0% | 5.4 | 1.1% | 20.1 | 1.5% | 42.5 | 2.9% |
| Interest expense, net | 12.1 | 2.8% | 11.0 | 2.3% | 36.6 | 2.8% | 30.0 | 2.1% |
| (Loss) income before income taxes | (3.6) | (0.8%) | (5.6) | (1.2%) | (16.5) | (1.3%) | 12.5 | 0.9% |
| Income tax (benefit) expense | (0.5) | (0.1%) | (3.3) | (0.7%) | (0.9) | (0.1%) | 2.6 | 0.2% |
| Net (loss) income | $(3.1) | (0.7%) | $(2.3) | (0.5%) | $(15.7) | (1.2%) | $9.9 | 0.7% |
| Net (loss) income per share: |  |  |  |  |  |  |  |  |
| Basic | $(0.14) |  | $(0.10) |  | $(0.69) |  | $0.44 |  |
| Diluted | $(0.14) |  | $(0.10) |  | $(0.69) |  | $0.44 |  |
| Weighted-average number of common shares: |  |  |  |  |  |  |  |  |
| Basic | 22.6 |  | 22.5 |  | 22.6 |  | 22.4 |  |
| Diluted | 22.6 |  | 22.5 |  | 22.6 |  | 22.6 |  |

The percentage of total net sales, by dollar volume, was as follows:

|  | Three Months Ended September 28, 2024 | September 30, 2023 | Nine Months Ended September 28, 2024 | September 30, 2023 |
| --- | ---: | ---: | ---: | ---: |
| Retail stores | 87.8% | 86.6% | 87.9% | 87.1% |
| Online, phone, chat and other | 12.2% | 13.4% | 12.1% | 12.9% |
| Total Company | 100.0% | 100.0% | 100.0% | 100.0% |

### 19 \| 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION

The components of total net sales change, including comparable net sales changes, were as follows:

| Sales change rates: | Three Months Ended September 28, 2024 | September 30, 2023 | Nine Months Ended September 28, 2024 | September 30, 2023 |
| --- | ---: | ---: | ---: | ---: |
| Retail comparable-store sales (1) | (7%) | (14%) | (9%) | (11%) |
| Online, phone and chat | (18%) | (14%) | (17%) | (13%) |
| Total Retail comparable sales change (1) | (9%) | (14%) | (10%) | (11%) |
| Net opened/closed stores and other | (1%) | 1% | 0% | 1% |
| Total Company | (10%) | (13%) | (10%) | (10%) |

(1) Stores are included in the comparable-store calculations in the 13th full month of operations. Stores that have been remodeled or repositioned

within the same shopping center remain in the comparable-store base.

Other sales metrics were as follows:

|  | Three Months Ended September 28, 2024 | September 30, 2023 | Nine Months Ended September 28, 2024 | September 30, 2023 |
| --- | ---: | ---: | ---: | ---: |
| Average sales per store (1) (in thousands) | $2,670 | $2,952 |  |  |
| Average sales per square foot (1) | $863 | $963 |  |  |
| Stores \> $2 million in net sales (2) | 60% | 67% |  |  |
| Stores \> $3 million in net sales (2) | 20% | 27% |  |  |
| Average revenue per smart bed unit (3) | $5,771 | $5,640 | $5,778 | $5,822 |

(1) Trailing-twelve months Total Retail comparable sales per store open at least one year.

(2) Trailing-twelve months for stores open at least one year (excludes online, phone and chat sales).

(3) Represents Total Retail net sales divided by Total Retail smart bed units.

The number of retail stores operating was as follows:

|  | Three Months Ended September 28, 2024 | September 30, 2023 | Nine Months Ended September 28, 2024 | September 30, 2023 |
| --- | ---: | ---: | ---: | ---: |
| Beginning of period | 646 | 672 | 672 | 670 |
| Opened | 1 | 8 | 11 | 27 |
| Closed | (4) | (2) | (40) | (19) |
| End of period | 643 | 678 | 643 | 678 |

### 20 \| 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION

### Comparison of Three Months Ended September 28, 2024 with Three Months Ended September 30, 2023

#### Net sales

Net sales for the three months ended September 28, 2024 of $427 million decreased 10% from $473 million for the

same period one year ago due to the ongoing weakness in the mattress industry and consumers continuing to scrutinize

their spending.

The net sales change consisted primarily of an 9% comparable sales decrease in Total Retail.

The $46 million net sales decrease compared with the same period one year ago was comprised of the following: (i) a

$27 million decrease in Retail comparable net sales; (ii) a $12 million decrease from online, phone and chat; and (iii) a $7

million decrease from net store closings and other. Total Retail smart bed unit sales decreased 12% compared with the

prior year. Total Retail average revenue per smart bed unit increased by 2% to $5,771, compared with $5,640 in the

prior-year period.

#### Gross profit

Gross profit of $260 million for the three months ended September 28, 2024 decreased by $12 million, or 4%, compared

with $271 million for the same period one year ago. The gross profit rate increased to 60.8% of net sales for the three

months ended September 28, 2024, compared with 57.4% for the prior-year comparable period.

The current-year gross profit rate increase of 3.4 ppt. was mainly due to: (i) year-over-year product cost reductions

through value engineering and ongoing supplier negotiations, increased the rate by 1.7 ppt; (ii) a favorable product mix,

increased the rate by 1.0 ppt; (iii) and efficiency gains in our home delivery and logistics operations, increased the rate by

0.7 ppt. In addition, the gross profit rate may fluctuate from quarter to quarter due to a variety of other factors, including

changes in warranty expenses, return and exchange costs, manufacturing and supply chain operations and performance-

based incentive compensation.

#### Sales and marketing expenses

Sales and marketing expenses for the three months ended September 28, 2024 were $205 million, or 48.2% of net sales,

compared with $221 million, or 46.8% of net sales, for the same period one year ago. The current-year sales and

marketing expenses rate increase of 1.4 ppt. was primarily due to the deleveraging impact of an 10% net sales decline

offset by a 7% decrease in expenses including a 4% lower media spend.

#### General and administrative expenses

General and administrative (G&A) expenses totaled $33 million, or 7.8% of net sales, for the three months ended

September 28, 2024, compared with $32 million, or 6.8% of net sales, in the prior-year period. The $1 million increase in

G&A expenses consisted mainly of: (i) a $1.9 million year-over-year increase in company-wide, performance-based

incentive compensation; offset by (ii) a $0.6 million decrease in employee compensation on lower headcount; and (iii) a

$0.2 million decrease in other miscellaneous expenses. The G&A expenses rate increased by 1.0 ppt. in the current-year

period, compared with the same period one year ago due to the items discussed above offset by the deleveraging

impact of lower net sales.

#### Research and development expenses

Research and development (R&D) expenses decreased to $11 million for the three months ended September 28, 2024,

compared with $13 million with the same period last year primarily due to lower headcount and outside services. While

the Company’s consumer innovation pipeline remains robust, it is re-prioritizing R&D resources in this highly constrained

environment.

#### Interest expense, net

Interest expense, net increased to $12 million for the three months ended September 28, 2024, compared with $11

million for the same period one year ago. The $1 million increase was mainly driven by a higher weighted-average

interest rate compared with the same period one year ago.

### 21 \| 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION

#### Restructuring Costs

In the fourth quarter of 2023, the Company initiated cost reduction actions to reduce operating expenses and accelerate

gross margin initiatives, and recognized $15.7 million of restructuring costs in that quarter. In addition to the costs

incurred in 2023, the Company incurred an additional $2.0 million and $14.4 million of restructuring costs during the

three and nine months ended September 28, 2024, respectively. Charges incurred related to this initiative were

comprised of contract termination costs, severance and employee-related benefits, professional fees and other, and

asset impairment charges and are included in the restructuring costs line in the Company’s consolidated statement of

operations. The Company expects an additional $2 million to $3 million of restructuring costs to be incurred through the

remainder of 2024, primarily due to lease contract termination costs.

#### Income tax (benefit) expense

Income tax benefit totaled $0.5 million for the three months ended September 28, 2024, compared with income tax

benefit of $3 million for the same period last year. The change in income tax benefit was primarily due to the impact of

the loss before income tax levels.

### Comparison of Nine Months Ended September 28, 2024 with Nine Months Ended September 30, 2023

#### Net sales

Net sales for the nine months ended September 28, 2024 decreased by $152 million, or 10%, to $1.3 billion, compared

with $1.5 billion for the same period one year ago due to the ongoing weakness in the mattress industry and consumers

continuing to scrutinize their spending.

The net sales decrease consisted primarily of an 10% comparable sales decrease in Total Retail. For additional details,

see the components of total net sales change on page 19.

The $152 million net sales decrease compared with the same period one year ago was comprised of the following: (i) an

$112 million decrease in Retail comparable net sales; (ii) a $31 million decrease in online, phone and other sales; and (iii)

a $9 million decrease resulting from net store closings. Total smart bed unit sales declined 10% compared with the same

period one year ago. Average revenue per smart bed unit in Total Retail decreased by 1% to $5,778, compared with

$5,822 in the prior-year period.

#### Gross profit

Gross profit of $777 million for the nine months ended September 28, 2024 decreased by $68 million, or 8%, compared

with $846 million for the same period one year ago. The gross profit rate increased to 59.5% of net sales for the nine

months ended September 28, 2024, compared to 58.0% in the prior-year comparable period.

The current-year gross profit rate increase of 1.5 ppt. was impacted by: (i) year-over-year product cost reductions

through value engineering and ongoing supplier negotiations, increased the rate by 1.1 ppt (ii) favorable pricing actions

taken over the last twelve months increased the rate by 1.0 ppt; (iii) efficiency gains in home delivery and logistics

operations, increased the rate by 0.7 ppt; partially offset by (iv) product mix of FlexFit smart adjustable bases, which

pressured the rate by 1.0 ppt; and (v) lower delivered smart bed volume deleveraged the rate by 0.2 ppt. In addition, the

gross profit rate may fluctuate from quarter to quarter due to a variety of other factors, including changes in warranty

expenses, manufacturing and supply chain operations and performance-based incentive compensation.

#### Sales and marketing expenses

Sales and marketing expenses for the nine months ended September 28, 2024 were $596 million, or 45.7% of net sales,

compared with $649 million, or 44.5% of net sales, for the same period one year ago. The current-year sales and

marketing expenses rate increase of 1.2 ppt. was primarily due to deleveraging impact of a 10% net sales decline offset

by a 8% decrease in expenses including 6% lower media spend.

### 22 \| 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION

#### General and administrative expenses

General and administrative (G&A) expenses totaled $112 million, or 8.6% of net sales, for the nine months

ended September 28, 2024, compared with $111 million, or 7.6% of net sales, in the prior-year period. The $1

million increase in G&A expenses consisted of: (i) a $2.6 million year-over-year increase in company-wide, performance-

based incentive compensation; (ii) a $0.8 million increase in technology investments; (iii) an increase in miscellaneous

other expenses of $3.1 million, which benefited during the same period one year ago from legal and insurance

settlements of $1.8 million; largely offset by (iv) a $4.4 million reduction in employee compensation on lower headcount;

and (v) a $1.1 million decrease in other occupancy expenses. The G&A expenses rate increased by 1.0 ppt. in the

current-year period, compared with the same period one year ago due to the deleveraging impact of the 10% net sales

decrease.

#### Research and development expenses

Research and development (R&D) expenses decreased by 19% to $35 million for the nine months ended September 28,

2024, compared with $43 million for the same period one year ago on lower outside services and headcount. While the

Company’s consumer innovation pipeline remains robust, it is re-prioritizing R&D resources in this highly constrained

environment.

#### Interest expense, net

Interest expense, net increased to $37 million for the nine months ended September 28, 2024, compared with $30

million for the same period one year ago. The $7 million increase was mainly driven by a higher weighted-average

interest rate compared with the same period one year ago.

#### Restructuring Costs

In the fourth quarter of 2023, the Company initiated cost reduction actions to reduce operating expenses and accelerate

gross margin initiatives, and recognized $15.7 million of restructuring costs in that quarter. In addition to the costs

incurred in 2023, the Company incurred $14.4 million of restructuring costs in the first nine months of 2024. Charges

incurred related to this initiative were comprised of contract termination costs, severance and employee-related benefits,

professional fees and other, and asset impairment charges and are included in the restructuring costs line in the

Company’s consolidated statement of operations. The Company expects an additional $2 million to $3 million of

restructuring costs to be incurred through the remainder of 2024, primarily due to lease contract termination costs.

#### Income tax (benefit) expense

Income tax benefit totaled $0.9 million for the nine months ended September 28, 2024, compared with income tax

expense of $3 million last year. The change in income tax expense was primarily due to the change in (loss) income

before income taxes levels and the impact of discrete tax expenses. Discrete tax expense, primarily stock-based

compensation tax shortfalls, was $2.6 million for the nine months ended September 28, 2024, compared to $1.1 million

for the same period last year.

### Liquidity and Capital Resources

Managing liquidity and capital resources is an important part of the Company’s commitment to deliver superior

shareholder value over time.

The Company’s primary sources of liquidity are cash flows provided by operating activities and cash available under its

$680 million revolving credit facility, as amended. As of September 28, 2024, the Company does not have any off-

balance sheet financing other than its $7 million in outstanding letters of credit. The cash generated from ongoing

operations and cash available under the revolving credit facility are expected to be adequate to maintain operations,

and fund anticipated expansion, strategic initiatives and contractual obligations such as lease payments and capital

commitments for new retail stores for the foreseeable future.

Cash and cash equivalents totaled $1.6 million and $2.5 million at September 28, 2024 and December 30, 2023,

respectively. Significant changes in cash and cash equivalents during the nine months ended September 28, 2024

primarily consisted of $51 million of cash provided by operating activities, offset by a $31 million decrease in short-term

### 23 \| 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION

borrowings, $17 million of cash used to purchase property and equipment, and $3 million of cash used to issue notes

receivable.

The following table summarizes cash flows (in millions). Amounts may not add due to rounding differences:

| Total cash provided by (used in): | Nine Months Ended September 28, 2024 | September 30, 2023 |
| --- | ---: | ---: |
| Operating activities | $50.8 | $31.8 |
| Investing activities | (20.0) | (49.3) |
| Financing activities | (31.8) | 16.6 |
| Net decrease in cash and cash equivalents | $(0.9) | $(0.9) |

Net cash provided by operating activities for the nine months ended September 28, 2024 was $51 million, compared

with $32 million for the nine months ended September 30, 2023. Significant components of the year-over-year change in

cash provided by operating activities included: (i) a $25 million fluctuation in inventory due to lower sales volumes and

operational improvements; (ii) a $22 million fluctuation in customer prepayments; and (iii) a $8 million fluctuation in

accrued compensation and benefits; partially offset by (iii) a $26 million decrease in net income for the nine months

ended September 28, 2024 compared with the nine months ended September 30, 2023; and (iv) a $9 million fluctuation

in other accruals and liabilities.

Net cash used in investing activities for the nine months ended September 28, 2024 was $20 million, compared with $49

million for the nine months ended September 30, 2023. Cash used to purchase property and equipment was $17 million

for the nine months ended September 28, 2024, compared with $48 million for the same period one year ago. In

addition, the Company issued $3 million of notes receivable during the nine months ended September 28, 2024.

Net cash used in financing activities was $32 million for the nine months ended September 28, 2024, compared with net

cash provided by financing activities of $17 million for the same period last year. Short-term borrowings decreased by

$31 million during the current-year period due to a $23 million decrease in borrowings under the revolving credit facility

to $517 million and a $8 million decrease in book overdrafts, which are included in the net change in short-term

borrowings. During the nine months ended September 28, 2024, the Company repurchased $1 million of its stock

compared with $4 million (based on settlement dates, in connection with the vesting of employee restricted stock

awards) during the same period one year ago. The Company made no share repurchases under its Board-approved

share repurchase program in either period.

In the second quarter of fiscal 2022, the Company suspended share repurchases under its Board-approved share

repurchase program. At September 28, 2024, there was $348 million remaining authorization under the Board-approved

$600 million share repurchase program. There is no expiration date governing the period over which the Company can

repurchase shares.

At September 28, 2024, the Company had $517 million of borrowings under its revolving credit facility, $7 million in

outstanding letters of credit and net liquidity available under the credit facility of $156 million. Total availability under its

revolving credit facility was $680 million, which amortizes by $2.5 million per quarter through December 2026. At

September 28, 2024, the Company’s leverage ratio as defined in the credit agreement was 4.2x versus the permissible

net leverage ratio of 5.0x, the weighted-average interest rate on borrowings under the credit facility was 8.2% and the

Company was in compliance with all financial covenants.

### 24 \| 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION

#### Index

### Non-GAAP Data Reconciliations

#### Earnings before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA)

The Company defines earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA) as net income

plus: income tax expense, interest expense, depreciation and amortization, stock-based compensation, restructuring

costs and asset impairments. Management believes Adjusted EBITDA is a useful indicator of its financial performance

and its ability to generate cash from operating activities. The Company’s definition of Adjusted EBITDA may not be

comparable to similarly titled definitions used by other companies. The table below reconciles Adjusted EBITDA, which

is a non-GAAP financial measure, to the comparable GAAP financial measure.

Adjusted EBITDA calculations are as follows (in thousands):

|  | Three Months Ended September 28, 2024 | September 30, 2023 | Trailing-Twelve Months Ended September 28, 2024 | September 30, 2023 |
| --- | ---: | ---: | ---: | ---: |
| Net (loss) income | $(3,136) | $(2,318) | $(40,857) | $4,471 |
| Income tax (benefit) expense | (489) | (3,253) | (7,966) | 1,346 |
| Interest expense | 12,057 | 10,958 | 49,313 | 37,641 |
| Depreciation and amortization | 15,859 | 18,200 | 67,335 | 72,338 |
| Stock-based compensation | 1,432 | 982 | 13,523 | 15,511 |
| Restructuring costs | 1,963 | — | 30,110 | — |
| Asset impairments | — | 292 | 198 | 491 |
| Adjusted EBITDA | $27,686 | $24,861 | $111,656 | $131,798 |

#### Free Cash Flow

The Company’s “free cash flow” data is considered a non-GAAP financial measure and is not in accordance with, or

preferable to, “net cash provided by operating activities,” or GAAP financial data. However, the Company is providing

this information as it believes it facilitates analysis for investors and financial analysts.

The following table summarizes free cash flow calculations (in thousands):

|  | Nine Months Ended September 28, 2024 | September 30, 2023 | Trailing-Twelve Months Ended September 28, 2024 | September 30, 2023 |
| --- | ---: | ---: | ---: | ---: |
| Net cash provided by (used in) operating activities | $50,824 | $31,816 | $9,980 | $(12,168) |
| Subtract: Purchases of property and equipment | 17,218 | 48,022 | 26,252 | 64,668 |
| Free cash flow | $33,606 | $(16,206) | $(16,272) | $(76,836) |

### 25 \| 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION

#### Index

### Non-GAAP Data Reconciliations (continued)

#### Return on Invested Capital (Adjusted ROIC)

Adjusted ROIC is a financial measure the Company uses to determine how efficiently it deploys its capital. It quantifies

the return the Company earns on its adjusted invested capital. Management believes Adjusted ROIC is also a useful

metric for investors and financial analysts. The Company computes Adjusted ROIC as outlined below. Its definition and

calculation of Adjusted ROIC may not be comparable to similarly titled definitions and calculations used by other

companies.

The tables below reconcile adjusted net operating profit after taxes (Adjusted NOPAT) and total adjusted invested

capital, which are non-GAAP financial measures, to the comparable GAAP financial measures (in thousands):

| Adjusted net operating profit after taxes (Adjusted NOPAT) | Trailing-Twelve Months Ended September 28, 2024 | September 30, 2023 |
| --- | ---: | ---: |
| Operating income | $490 | $43,458 |
| Add: Operating lease expense (1) | 27,371 | 27,497 |
| Less: Income taxes (2) | (5,474) | (1,168) |
| Adjusted NOPAT | $22,387 | $69,787 |
| Average adjusted invested capital |  |  |
| Total deficit | $(448,784) | $(420,687) |
| Add: Long-term debt (3) | 516,761 | 488,338 |
| Add: Operating lease obligations (4) | 401,153 | 439,722 |
| Total adjusted invested capital at end of period | $469,130 | $507,373 |
| Average adjusted invested capital (5) | $502,494 | $469,782 |
| Adjusted return on invested capital (Adjusted ROIC) (6) | 4.5% | 14.9% |

(1) Represents the interest expense component of lease expense included in the Company’s financial statements under ASC 842, *Leases.*

(2) Reflects annual effective income tax rates, before discrete adjustments, of 19.6% and 1.6% for September 28, 2024 and September 30, 2023,

respectively.

(3) Long-term debt includes existing finance lease liabilities.

(4) Reflects operating lease liabilities included in the Company’s financial statements under ASC 842.

(5) Average adjusted invested capital represents the average of the last five fiscal quarters’ ending adjusted invested capital balances.

(6) Adjusted ROIC equals Adjusted NOPAT divided by average adjusted invested capital.

Note - the Company’s adjusted ROIC calculation and data are considered non-GAAP financial measures and are not in accordance with, or preferable

to, GAAP financial data. However, the Company is providing this information as it believe it facilitates analysis of the Company's financial performance

by investors and financial analysts.

GAAP - generally accepted accounting principles in the U.S.

### Critical Accounting Policies

The Company discusses its critical accounting policies and estimates in *Management’s Discussion and Analysis of*

*Financial Condition and Results of Operations* in the Company’s Annual Report on Form 10-K for the fiscal year ended

December 30, 2023. There were no significant changes in the Company’s critical accounting policies since the end of

fiscal 2023.

### 26 \| 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION

#### Index

## Market risk

As filed, 480 characters.

The Company is exposed to changes in market-based short-term interest rates that will impact net interest expense. If

overall interest rates were one percentage point higher than current rates, annual net income would decrease by

$4.2 million based on the $517 million of borrowings under the credit facility at September 28, 2024. The Company does

not manage the interest-rate volatility risk of borrowings under the credit facility through the use of derivative

instruments.

## Controls and procedures

As filed, 1,671 characters.

### Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures, as defined in Exchange Act Rule 13a-15(e), that are

designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under

the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time

periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is

accumulated and communicated to the Company’s management, including its principal executive officer and principal

financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required

disclosure. The Company’s management, with the participation of its principal executive officer and principal financial

officer, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures as

of the end of the period covered by this quarterly report. Based on this evaluation, its principal executive officer and

principal financial officer concluded that the Company’s disclosure controls and procedures were effective as of the end

of the period covered by this quarterly report.

### Changes in Internal Control

There were no changes in the Company’s internal control over financial reporting during the fiscal quarter ended

September 28, 2024, that have materially affected, or are reasonably likely to materially affect, the Company’s internal

control over financial reporting.

### 27 \| 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION

#### Index

## Risk factors

As filed, 1,065 characters.

The Company’s business, financial condition and operating results are subject to a number of risks and uncertainties,

including both those that are specific to the Company’s business and others that affect all businesses operating in a

global environment. Investors should carefully consider the information in this report under the heading, *Management’s*

*Discussion and Analysis of Financial Condition and Results of Operations*, and also the information under the heading,

*Risk Factors*, in the Company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form

10-Q. The risk factors discussed in the Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q

including this Quarterly Report on Form 10-Q do not identify all risks that the Company faces because its business

operations could also be affected by additional risk factors that are not presently known to the Company or that it

currently considers to be immaterial to its operations.

### 28 \| 3Q 2024 FORM 10-Q SLEEP NUMBER CORPORATION

#### Index

Filed Nov 5, 2024.
Source: SEC EDGAR, the filing index for accession 0000827187-24-000091. Last ingested by Listed: Oct 24, 2026, 14:57 ET. No prices; not investment advice.
